<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Bacterial meningitis in the neonate: Treatment and outcome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Bacterial meningitis in the neonate: Treatment and outcome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Bacterial meningitis in the neonate: Treatment and outcome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carol J Baker, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheldon L Kaplan, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Karen M Puopolo, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carrie Armsby, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 05, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bacterial meningitis is more common in the first month than at any other time of life [
         <a href="#rid1">
          1
         </a>
         ]. Despite advances in neonatal intensive care, meningitis in the neonate remains a devastating disease.
        </p>
        <p>
         The treatment and outcome of bacterial meningitis in the neonate (age &lt;1 month) will be discussed here. The clinical features, diagnosis, and complications of bacterial meningitis are discussed separately, as is bacterial meningitis in older children:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6005.html" rel="external">
          "Bacterial meningitis in the neonate: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6017.html" rel="external">
          "Bacterial meningitis in the neonate: Neurologic complications"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5968.html" rel="external">
          "Bacterial meningitis in children older than one month: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6010.html" rel="external">
          "Bacterial meningitis in children older than one month: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          SUPPORTIVE CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial care for all neonates with meningitis should be provided in an intensive care unit setting. Supportive care measures are a crucial part of the management of neonates with bacterial meningitis [
         <a href="#rid2">
          2
         </a>
         ]. These may include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of cardiovascular instability or shock  (
         <a class="graphic graphic_algorithm graphicRef128082" href="/z/d/graphic/128082.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/126605.html" rel="external">
          "Neonatal shock: Management"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Provision of oxygen and additional respiratory support as needed (see
         <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">
          "Respiratory support, oxygen delivery, and oxygen monitoring in the newborn"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5032.html" rel="external">
          "Overview of mechanical ventilation in neonates"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Careful fluid therapy, avoiding both hypo- and hypervolemia (see
         <a class="medical medical_review" href="/z/d/html/5065.html" rel="external">
          "Fluid and electrolyte therapy in newborns"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevention and management of hypoglycemia (see
         <a class="medical medical_review" href="/z/d/html/101425.html" rel="external">
          "Management and outcome of neonatal hypoglycemia"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Control of seizures (see
         <a class="medical medical_review" href="/z/d/html/6201.html" rel="external">
          "Treatment of neonatal seizures"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nutritional support (see
         <a class="medical medical_review" href="/z/d/html/5014.html" rel="external">
          "Approach to enteral nutrition in the premature infant"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15634.html" rel="external">
          "Parenteral nutrition in infants and children"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          ANTIMICROBIAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         For neonates whose clinical and initial cerebrospinal fluid (CSF) findings are suggestive of bacterial meningitis (eg, CSF pleocytosis, increased CSF protein and/or decreased CSF glucose, organism present on Gram stain), broad-spectrum antimicrobial therapy should be initiated as soon as possible. An appropriate regimen includes agents that have adequate CSF penetration at appropriate doses to achieve adequate levels in the CSF.
        </p>
        <p>
         When the results of the CSF and blood cultures, including antimicrobial susceptibilities, are available, antimicrobial therapy is tailored to the specific pathogen. (See
         <a class="local">
          'Definitive therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Empiric therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial choice of antimicrobials for suspected bacterial meningitis in the neonate is based on the timing of onset (ie, early versus late onset), likely pathogens  (
         <a class="graphic graphic_table graphicRef61061" href="/z/d/graphic/61061.html" rel="external">
          table 1
         </a>
         ), and local susceptibility patterns within the nursery or neonatal intensive care unit and within the community. (See
         <a class="medical medical_review" href="/z/d/html/6005.html" rel="external">
          "Bacterial meningitis in the neonate: Clinical features and diagnosis", section on 'Etiology'
         </a>
         .)
        </p>
        <p>
         Often, at the first sign of illness, empiric therapy for neonatal sepsis is initiated as summarized in the table  (
         <a class="graphic graphic_table graphicRef102574" href="/z/d/graphic/102574.html" rel="external">
          table 2
         </a>
         ) and discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5046.html" rel="external">
          "Management and outcome of sepsis in term and late preterm neonates", section on 'Initial empiric therapy'
         </a>
         .)
        </p>
        <p>
         When there is clinical concern for meningitis (eg, critical illness, CSF pleocytosis, organism present on CSF Gram stain, or other suggestive CSF parameters), the empiric regimen should be modified as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Discontinue the aminoglycoside.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Add an extended-spectrum cephalosporin (eg,
         <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">
          cefotaxime
         </a>
         [where available],
         <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">
          ceftazidime
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">
          cefepime
         </a>
         );
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         should
         <strong>
          not
         </strong>
         be used in neonates, because it displaces bilirubin from albumin binding sites, which might contribute to kernicterus and may precipitate if used with intravenous calcium, leading to severe reactions [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In addition, for most neonates with CSF pleocytosis and negative CSF Gram stain, empiric
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         therapy for herpes simplex virus is warranted (after performing appropriate testing), as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6040.html" rel="external">
          "Neonatal herpes simplex virus infection: Management and prevention", section on 'Initial antiviral therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Adding an expanded-spectrum cephalosporin to the empiric regimen provides optimal activity in the CSF against ampicillin-resistant gram-negative enteric organisms and pneumococci. High rates of
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          ampicillin
         </a>
         resistance among
         <em>
          Escherichia
         </em>
         <em>
          coli
         </em>
         isolates and a link between maternal intrapartum ampicillin prophylaxis and
         <em>
          E. coli
         </em>
         resistance have been reported among preterm neonates managed in the neonatal intensive care unit setting [
         <a href="#rid5">
          5,6
         </a>
         ]. However, this not the case in late preterm or term newborn infants, in whom group B streptococcus (GBS) remains the most likely early-onset pathogen [
         <a href="#rid2">
          2,5
         </a>
         ]. Ampicillin resistance is a concern in community-acquired late-onset infections in term and preterm neonates. In one survey of febrile infants &lt;90 days old presenting to an emergency department, nearly 80 percent of infants with meningitis had ampicillin-resistant pathogens [
         <a href="#rid7">
          7
         </a>
         ]. The authors of the study conclude that the initial regimen should contain both ampicillin and an expanded-spectrum cephalosporin because of the risk of GBS and
         <em>
          Listeria monocytogenes
         </em>
         infection in this age group, as well as for ampicillin-resistant gram-negative enteric organisms. We agree with this practice.
        </p>
        <p>
         Antibiotic coverage generally should not be narrowed based on the Gram stain results, because they are subject to observer misinterpretation. Empiric broad-spectrum therapy should be continued pending laboratory identification of the organism and susceptibility results (see
         <a class="local">
          'Definitive therapy'
         </a>
         below). However, if the Gram stain suggests a pathogen that is not adequately covered with the empiric regimen, the regimen should be adjusted accordingly. For example, if initial empiric therapy consists of
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         plus an extended-spectrum cephalosporin and the Gram stain suggests
         <em>
          L. monocytogenes
         </em>
         ,
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          ampicillin
         </a>
         should be added. If meningitis resulting from a multidrug-resistant (MDR) gram-negative organism is strongly suspected (eg, when the CSF Gram stain reveals gram-negative bacilli and positive screen for extended-spectrum beta-lactamase), the empiric regimen should substitute
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          meropenem
         </a>
         for the cephalosporin [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         In the neonatal intensive care unit setting, ongoing use of an expanded-spectrum cephalosporin should be restricted to neonates with suspected bacterial meningitis based on clinical findings
         <strong>
          and
         </strong>
         CSF parameters. When use of third- or fourth-generation cephalosporins is routine (eg, when they are used more broadly for all neonates treated for "rule out sepsis"), rapid emergence of resistant strains (especially
         <em>
          Enterobacter cloacae
         </em>
         ,
         <em>
          Klebsiella pneumoniae
         </em>
         , and
         <em>
          Serratia
         </em>
         species) can occur [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Definitive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the causative agent and the in vitro antimicrobial susceptibility results are known, empiric antimicrobial therapy should be altered accordingly. Guidance for treating the most common causes of neonatal meningitis is provided below.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Group B streptococcus
         </span>
         <span class="headingEndMark">
          —
         </span>
         GBS is uniformly susceptible to penicillin and
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          ampicillin
         </a>
         .
         <a class="drug drug_pediatric" data-topicid="12687" href="/z/d/drug information/12687.html" rel="external">
          Penicillin G
         </a>
         monotherapy is the appropriate definitive therapy once the neonate is improving clinically and repeat lumbar puncture (LP) documents CSF sterilization (see
         <a class="local">
          'Repeat lumbar puncture'
         </a>
         below). Duration of treatment is 14 to 21 days (see
         <a class="local">
          'Duration'
         </a>
         below). Treatment of neonatal GBS infections, including GBS meningitis, is summarized in the table and discussed in detail separately  (
         <a class="graphic graphic_table graphicRef66906" href="/z/d/graphic/66906.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5961.html" rel="external">
          "Group B streptococcal infection in neonates and young infants", section on 'Definitive therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Escherichia coli and other gram-negative organisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          Ampicillin
         </a>
         is the agent of choice for neonatal meningitis resulting from ampicillin-susceptible strains of
         <em>
          E. coli
         </em>
         .
        </p>
        <p>
         Ampicillin-resistant
         <em>
          E. coli
         </em>
         and other gram-negative organisms usually are initially treated with a combination of an extended-spectrum cephalosporin (eg,
         <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">
          cefotaxime
         </a>
         if available)
         <strong>
          plus
         </strong>
         an aminoglycoside, usually
         <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">
          gentamicin
         </a>
         ; the aminoglycoside is discontinued once sterility of the CSF is documented. Appropriate monotherapy is continued to complete a minimum of 21 days.
        </p>
        <p>
         The prevalence of antimicrobial resistance among gram-negative isolates has increased markedly since the 1990s [
         <a href="#rid10">
          10
         </a>
         ]. Resistance in association with production of AmpC beta-lactamases or extended-spectrum beta-lactamases (ESBLs) occurs primarily, but not exclusively, in
         <em>
          E. coli, Klebsiella
         </em>
         species, and
         <em>
          Enterobacter
         </em>
         species. Carbapenemase-producing gram-negative organisms, especially
         <em>
          Klebsiella pneumoniae
         </em>
         ,
         <em>
          E. coli
         </em>
         , and
         <em>
          Enterobacter cloacae
         </em>
         , have also emerged but are uncommon in newborn infants [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Infections caused by noncarbapenemase-producing MDR enteric organisms are generally treated with
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          meropenem
         </a>
         . Meropenem should be administered for the entire course of therapy for neonates with meningitis that is caused by MDR gram-negative organisms. The hospital microbiology laboratory should provide assistance for appropriate testing of carbapenemase-producing gram-negative organisms for MDR patterns.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Other pathogens
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coagulase-negative staphylococci
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          Vancomycin
         </a>
         is the antimicrobial of choice for proven meningitis caused by coagulase-negative staphylococci. These organisms rarely invade the meninges except as a complication of bacteremia accompanying intraventricular hemorrhage in very low birth weight infants (birth weight &lt;1500 g) or as a result of surgical manipulations or placement of a ventriculoperitoneal shunt. Such infections invariably are of late onset.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Sterilization of the CSF usually is achieved promptly after initiation of
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         unless shunt material has not been removed. If the CSF is persistently positive, consideration should be given to adding
         <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">
          rifampin
         </a>
         (5 mg/kg every 12 hours) to vancomycin for synergy. However, it is uncertain whether combination therapy truly improves clearance of the infection. (See
         <a class="medical medical_review" href="/z/d/html/1286.html" rel="external">
          "Infections of cerebrospinal fluid shunts", section on 'Staphylococci'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Listeria
          </em>
         </strong>
         – The combination of
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          ampicillin
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">
          gentamicin
         </a>
         is more effective than ampicillin alone in vitro and in animal models of infection, and it is appropriate for initial therapy  (
         <a class="graphic graphic_table graphicRef122593" href="/z/d/graphic/122593.html" rel="external">
          table 4
         </a>
         ). When the CSF has been sterilized and the infant has improved clinically, a 14- to 21-day course of treatment can be completed with ampicillin monotherapy. (See
         <a class="medical medical_review" href="/z/d/html/1303.html" rel="external">
          "Treatment and prevention of Listeria monocytogenes infection", section on 'Antibiotic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Staphylococcus
          </em>
         </strong>
         <strong>
         </strong>
         <strong>
          <em>
           aureus
          </em>
         </strong>
         – The standard therapy for methicillin-susceptible
         <em>
          S. aureus
         </em>
         (MSSA) meningitis is
         <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">
          nafcillin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">
          oxacillin
         </a>
         [
         <a href="#rid11">
          11,12
         </a>
         ]. Treatment duration is typically 14 days. The preferred therapy for methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA) meningitis is
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         [
         <a href="#rid11">
          11-13
         </a>
         ]. Treatment duration is at least 14 days. Some experts suggest adding
         <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">
          rifampin
         </a>
         to vancomycin for treatment of MRSA infection, but there are no clinical studies to suggest efficacy. Treatment of MSSA and MRSA infections is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6057.html" rel="external">
          "
          <i>
           Staphylococcus aureus
          </i>
          in children: Overview of treatment of invasive infections", section on 'Definitive antimicrobial therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         The duration of antibiotic therapy depends upon the results of CSF and blood cultures, the clinical course, and whether the neonate was pretreated with antibiotics prior to the LP.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Positive CSF culture
         </strong>
         – The suggested duration of antibiotic therapy for different causative organisms is as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         GBS or other gram-positive organisms (eg,
         <em>
          L. monocytogenes
         </em>
         or
         <em>
          Enterococcus
         </em>
         ) – A 14-day course is sufficient for neonates with an uncomplicated course [
         <a href="#rid14">
          14
         </a>
         ]
         <em>
          .
         </em>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          E. coli
         </em>
         or other gram-negative enteric pathogens – A 21-day course is the
         <strong>
          minimum
         </strong>
         for neonates with an uncomplicated course [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A longer course of therapy is required for neonates with meningitis whose course is complicated. Prolonged treatment, sometimes for as long as eight weeks, may be required for neonates with ventriculitis, abscesses, or multiple areas of infarction or hemorrhage with resulting encephalomalacia. (See
         <a class="medical medical_review" href="/z/d/html/6017.html" rel="external">
          "Bacterial meningitis in the neonate: Neurologic complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Negative CSF culture with positive blood culture and CSF pleocytosis
         </strong>
         – For neonates with CSF pleocytosis and bacteremia but a negative CSF culture (obtained before antibiotic therapy), we usually continue meningeal doses of antimicrobial therapy for 10 days for gram-positive bacteremia (eg, GBS) and 14 days for gram-negative bacteremia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Negative CSF and blood cultures
         </strong>
         – For neonates in whom cultures were obtained before antibiotic therapy and both blood and CSF cultures are negative after 48 hours, we suggest discontinuing antibiotic therapy. Negative cultures in the setting of CSF pleocytosis should prompt consideration of nonbacterial causes of meningitis (eg, herpes simplex virus [HSV], enterovirus). (See
         <a class="medical medical_review" href="/z/d/html/6005.html" rel="external">
          "Bacterial meningitis in the neonate: Clinical features and diagnosis", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pretreated or LP delayed
         </strong>
         – Some neonates may be exposed to antibiotics prior to undergoing LP (eg, because the LP is delayed due to clinical instability, because the mother received intrapartum antibiotic prophylaxis, or because the infant was receiving antibiotics for another reason [eg, prophylaxis for vesicoureteral reflux]). This can result in negative CSF culture. However, in most cases, other CSF parameters, (eg, cell count and protein concentration) will permit accurate diagnosis so long as the LP is not traumatic. (See
         <a class="medical medical_review" href="/z/d/html/6005.html" rel="external">
          "Bacterial meningitis in the neonate: Clinical features and diagnosis", section on 'Interpretation of cerebrospinal fluid'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our approach to managing pretreated neonates is as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For neonates in whom the LP was delayed because of clinical instability, meningeal doses of antimicrobial therapy should be continued until the LP can be safely performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The total duration of therapy in pretreated neonates depends upon the CSF evaluation and blood culture result:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Neonates with CSF pleocytosis and positive blood culture are treated for 10 days for gram-positive infection (eg, GBS) and 14 days for gram-negative infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For neonates with normal CSF profile and negative blood and CSF cultures, we usually discontinue antibiotic therapy when cultures are sterile after 48 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For neonates who have a CSF pleocytosis and negative blood and CSF cultures, we individualize the duration of meningitic doses of antimicrobial therapy based on clinical parameters, including whether there is a nonbacterial (eg, HSV, enterovirus) or noninfectious explanation for the pleocytosis (eg, intraventricular hemorrhage). (See
         <a class="medical medical_review" href="/z/d/html/6005.html" rel="external">
          "Bacterial meningitis in the neonate: Clinical features and diagnosis", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          ADJUNCTIVE THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adjunctive immunomodulatory therapy is
         <strong>
          not
         </strong>
         a routine part of management of neonatal meningitis. Though there is evidence from experimental models that immune modulation may positively impact the outcome of neonatal meningitis, the modalities that have undergone clinical investigation thus far have either been shown to be ineffective or they have not been adequately studied.
        </p>
        <p>
         In particular, we suggest
         <strong>
          not
         </strong>
         using glucocorticoid therapy to reduce the risk of neurologic sequelae in neonatal meningitis. There are limited data on the use of glucocorticoids in this setting. In a clinical trial involving 52 neonates randomly assigned to
         <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">
          dexamethasone
         </a>
         plus antibiotic therapy or antibiotic therapy alone, rates of mortality, neurologic disability, and hearing loss at two years were similar in both groups [
         <a href="#rid15">
          15
         </a>
         ]. In an observational study of 263 infants &lt;90 days old with bacterial meningitis, glucocorticoid therapy was not associated with lower mortality; however, only 8 percent of patients in this cohort received glucocorticoids [
         <a href="#rid16">
          16
         </a>
         ]. The role of dexamethasone therapy in older infants and children with bacterial meningitis is controversial and is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6026.html" rel="external">
          "Bacterial meningitis in children: Dexamethasone and other measures to prevent neurologic complications"
         </a>
         .)
        </p>
        <p>
         Other adjunctive therapies for neonatal sepsis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5046.html" rel="external">
          "Management and outcome of sepsis in term and late preterm neonates", section on 'Adjunctive therapies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/89456.html" rel="external">
          "Treatment and prevention of bacterial sepsis in preterm infants &lt;34 weeks gestation", section on 'Adjunct therapy to antibiotics'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          MONITORING RESPONSE TO THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H3844806603">
         <span class="h2">
          Ongoing evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The response to therapy and the potential development of complications are monitored with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serial neurologic examinations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment of the overall clinical status (eg, vital sign trends, temperature stability, need for hemodynamic or respiratory support).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Repeat blood cultures – In bacteremic neonates, a repeat blood culture should be performed to document sterility of the blood stream. The follow-up blood culture is usually obtained at the time when the initial blood culture is reported as positive.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Repeat examination of the cerebrospinal fluid (CSF). (See
         <a class="local">
          'Repeat lumbar puncture'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neuroimaging (See
         <a class="local">
          'Neuroimaging'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Most neonates with uncomplicated bacterial meningitis have clinical improvement within 24 to 48 hours of receiving appropriate antibiotic therapy. Clinical deterioration or failure to improve in this timeframe may suggest development of a complication (eg, obstructive ventriculitis, subdural effusion, brain abscess, intraventricular hemorrhage) or inadequate antimicrobial therapy. (See
         <a class="medical medical_review" href="/z/d/html/6017.html" rel="external">
          "Bacterial meningitis in the neonate: Neurologic complications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Repeat lumbar puncture
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest repeating the lumbar puncture (LP) 24 to 48 hours after initiating antimicrobial therapy for neonates with meningitis caused by group B streptococcus (GBS),
         <em>
          E. coli
         </em>
         , other gram-negatives, and
         <em>
          Listeria
         </em>
         and for neonates with a complicated course [
         <a href="#rid11">
          11,14
         </a>
         ]. This encompasses the majority of patients with neonatal meningitis.
        </p>
        <p>
         Reevaluation of the CSF 24 to 48 hours after initiation of antimicrobial therapy is important for several reasons [
         <a href="#rid17">
          17,18
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In severe cases, gram-negative organisms may persist for several days. Delayed sterilization of the CSF is associated with an increased risk of developing neurologic sequelae (see
         <a class="local">
          'Outcome'
         </a>
         below). This clinical scenario is uncommon with the routine use of an extended-spectrum cephalosporin as initial empiric therapy. By contrast, gram-positive bacteria usually clear from the CSF rapidly (within 24 hours) after initiation of appropriate antimicrobial therapy unless there is high bacterial burden in the CSF.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The persistent identification of organisms on a Gram stain may be an early indication of inadequacy of antimicrobial therapy (eg, the organism is not susceptible to the concentration of antibiotic that is attained in the CSF).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistence of viable organisms more than 48 hours after initiation of antimicrobial therapy is an indication for diagnostic neuroimaging because it can indicate a purulent focus (eg, obstructive ventriculitis) that can require additional intervention or increased duration of antimicrobial therapy. (See
         <a class="local">
          'Neuroimaging'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/6017.html" rel="external">
          "Bacterial meningitis in the neonate: Neurologic complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sterilization of the CSF is a criterion for discontinuing combination therapy for some pathogens (eg, GBS,
         <em>
          Listeria
         </em>
         ). (See
         <a class="local">
          'Definitive therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5961.html" rel="external">
          "Group B streptococcal infection in neonates and young infants", section on 'Definitive therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In uncomplicated neonatal meningitis, repeat CSF culture should generally be sterile. A positive culture obtained 48 hours after initiation of therapy raises a concern for obstructive ventriculitis or intraventricular hemorrhage. The additional evaluation and management of such infants should be individualized and undertaken in consultation with specialists in pediatric infectious diseases and pediatric neurosurgery. (See
         <a class="medical medical_review" href="/z/d/html/6017.html" rel="external">
          "Bacterial meningitis in the neonate: Neurologic complications", section on 'Ventriculitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Neuroimaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         We perform neuroimaging (typically with magnetic resonance imaging [MRI]) 48 to 72 hours before the anticipated end of therapy in all neonates with confirmed bacterial meningitis, even those with an apparently uncomplicated course. Neuroimaging may be warranted earlier in the course for neonates with signs suggesting neurologic complications. Neurologic complications should be considered if the neonate fails to improve clinically after 24 to 48 hours of appropriate antibiotic therapy. (See
         <a class="medical medical_review" href="/z/d/html/6017.html" rel="external">
          "Bacterial meningitis in the neonate: Neurologic complications"
         </a>
         .)
        </p>
        <p>
         MRI is preferred over contrast-enhanced computed tomography (CT) because MRI provides better anatomic detail, optimizes assessment of injury to white matter, and avoids radiation exposure [
         <a href="#rid19">
          19
         </a>
         ]. If there are focal findings that require extension of the course of antimicrobial therapy, treatment can be continued without interruption.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cranial ultrasound
         </strong>
         – Early in the course of meningitis, cranial ultrasound is the most practical neuroimaging technique, as it can be performed at the bedside. It is helpful for assessing ventricular size and the presence of intraventricular hemorrhage. Cranial ultrasound also can demonstrate ventriculitis, echogenic sulci, abnormal parenchymal echogenicities, and extracerebral fluid collections [
         <a href="#rid20">
          20,21
         </a>
         ]. In addition, because serial ultrasound studies can be performed safely at the bedside, it is useful in defining the progression of complications in infants with prolonged seizure activity or focal neurologic deficits [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6017.html" rel="external">
          "Bacterial meningitis in the neonate: Neurologic complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MRI
         </strong>
         – Similar to ultrasonography, early in the treatment course, MRI can demonstrate cerebral edema and ischemic lesions effectively, as well as leptomeningeal enhancement, ventriculitis, and infarction. Pus within the lateral ventricles can be seen as restricted diffusion. Later in the treatment course, contrast-enhanced MRI is useful in detecting cerebral abscesses, persistent cerebritis, areas of infarction or encephalomalacia, subdural empyema, hydrocephalus and degree of cerebral cortical, and white matter injury. (See
         <a class="medical medical_review" href="/z/d/html/6017.html" rel="external">
          "Bacterial meningitis in the neonate: Neurologic complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These findings may influence duration of antimicrobial therapy. (See
         <a class="local">
          'Duration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Contrast-enhanced neuroimaging (MRI or CT) is integral to the care of all neonates with meningitis caused by organisms that have a propensity for formation of intracranial abscesses. These include
         <em>
          Citrobacter
         </em>
         <em>
          koseri
         </em>
         ,
         <em>
          Serratia marcescens
         </em>
         ,
         <em>
          Proteus mirabilis
         </em>
         , and
         <em>
          Cronobacter sakazakii
         </em>
         [
         <a href="#rid23">
          23-28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6017.html" rel="external">
          "Bacterial meningitis in the neonate: Neurologic complications", section on 'Brain abscess'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2125105630">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long-term follow-up for survivors of neonatal meningitis includes monitoring of hearing, vision, and developmental status. Hearing should be evaluated by auditory brainstem response within four to six weeks of completing therapy (or when feasible in extremely preterm neonates) [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6297.html" rel="external">
          "Hearing loss in children: Screening and evaluation"
         </a>
         .)
        </p>
        <p>
         Survivors of neonatal meningitis are at risk for developmental delay and may be eligible to receive early intervention services in the United States (eligibility criteria vary by state). Appropriate referrals should be made as indicated. Developmental surveillance should continue throughout childhood. (See
         <a class="medical medical_review" href="/z/d/html/615.html" rel="external">
          "Developmental-behavioral surveillance and screening in primary care", section on 'Approach to surveillance'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          OUTCOME
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neonatal meningitis is a devastating disease. Advances in infant intensive care have reduced mortality, but morbidity remains high.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mortality and disability
         </strong>
         – In the contemporary era, mortality from neonatal meningitis is approximately 10 percent [
         <a href="#rid1">
          1,16,30-34
         </a>
         ]. However, survivors remain at high risk for neurologic sequelae and lifelong impairment, as discussed below [
         <a href="#rid31">
          31,33-35
         </a>
         ]. Approximately 15 to 20 percent of survivors have moderate to severe disability, and approximately 30 to 35 percent have mild disability. (See
         <a class="medical medical_review" href="/z/d/html/6017.html" rel="external">
          "Bacterial meningitis in the neonate: Neurologic complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a review of 101 term and late preterm neonates (ie, gestational ≥35 weeks) diagnosed with bacterial meningitis between 1979 and 1998, mortality declined from 17 percent in the early era (1979 to 1988) to 9 percent in the later era (1989 to 1998) [
         <a href="#rid36">
          36
         </a>
         ]. Among survivors, 19 percent had moderate or severe disability at one year of age (defined as severe cerebral palsy, moderate to severe developmental delay, blindness, and/or deafness).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognostic factors
         </strong>
         – Factors predictive of death or serious adverse sequelae from bacterial meningitis include [
         <a href="#rid32">
          32,33,36-44
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Low birth weight (&lt;2500 g) or preterm birth (&lt;37 weeks gestation)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History of clinical signs for &gt;24 hours before hospitalization
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Leukopenia (white blood cell &lt;5000/microL) and neutropenia at presentation
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Very high cerebrospinal fluid (CSF) protein (&gt;300 mg/dL) and/or very low CSF glucose (&lt;10 percent of blood glucose value)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Seizures continuing &gt;72 hours after hospitalization
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Focal neurologic deficits noted during the acute illness
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Requirement for mechanical ventilation or inotropes
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Delayed sterilization of the CSF
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Neuroimaging findings of meningeal inflammation are generally not predictive of neurologic outcome, but the presence and size of parenchymal lesions (eg, thrombi, encephalomalacia) do have prognostic significance. In particular, abscess formation is associated with neurologic sequelae [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes in preterm neonates
         </strong>
         – The outcome is generally worse in preterm low birth weight infants compared with term infants [
         <a href="#rid33">
          33,35
         </a>
         ]. In one study of 113 infants with bacterial meningitis, long-term motor disability (spasticity or paresis) was noted in 27 percent of preterm infants compared with 10 percent of term infants [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Similarly, outcomes for preterm neonates with bacterial meningitis are generally worse compared with preterm neonates without meningitis. In one study of very low birth weight infants (birth weight &lt;1500 g), after controlling for birth weight, intraventricular hemorrhage, chronic lung disease, and social risk factors, survivors of meningitis had a twofold higher risk of major neurologic disability (eg, cerebral palsy or abnormal tone, hydrocephalus, blindness, deafness, and severe developmental delay) at 20 months of age [
         <a href="#rid45">
          45
         </a>
         ]. In a large cohort study of extremely low birth weight (birth weight &lt;1000 g) infants, those with neonatal meningitis were more likely than uninfected infants to have cerebral palsy, neurodevelopmental impairment, and low mental developmental index scores [
         <a href="#rid46">
          46
         </a>
         ]. Long-term neurologic outcome in preterm infants is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/103308.html" rel="external">
          "Long-term neurodevelopmental impairment in infants born preterm: Risk assessment, follow-up care, and early intervention", section on 'Predicting outcome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes by causative organism
         </strong>
         – Outcomes vary according to the causative organism:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Group B streptococcus
         </strong>
         <strong>
          <em>
          </em>
         </strong>
         <strong>
          (GBS)
         </strong>
         – Reported mortality rates of neonatal GBS meningitis range from 5 to 11 percent [
         <a href="#rid39">
          39,46-48
         </a>
         ]. Long-term neurologic sequelae occur in approximately 20 to 40 percent of survivors [
         <a href="#rid49">
          49,50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In a study of 90 neonates diagnosed with GBS meningitis from 1998 through 2006, 5 percent of patients died acutely and an additional 5 percent died by three years of age [
         <a href="#rid48">
          48
         </a>
         ]. Among the survivors, 56 percent had age-appropriate development, 25 percent had mild-to-moderate impairment, and 19 percent had severe impairment.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Outcomes of GBS infection in neonates are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5961.html" rel="external">
          "Group B streptococcal infection in neonates and young infants", section on 'Outcome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           E
          </em>
         </strong>
         <strong>
          .
         </strong>
         <strong>
          <em>
           coli
          </em>
         </strong>
         – In a report of 325 young infants (71 percent were neonates, 35 percent were preterm) diagnosed with
         <em>
          E. coli
         </em>
         meningitis from 2001 to 2013, the overall mortality rate was 9 percent [
         <a href="#rid32">
          32
         </a>
         ]. Mortality was approximately threefold higher in preterm infants compared with term infants (17 versus 5 percent, respectively). Short-term morbidities included seizures (13 percent), subdural empyema (6 percent), intraventricular hemorrhage or hydrocephalus (5 percent), and cerebral venous thrombosis or stroke (3 percent). Long-term morbidities were not described. Preterm birth and severe hypoglycorrhachia (ie, CSF glucose &lt;10 percent of blood glucose level) were the strongest predictors of death.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1674223970">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110817.html" rel="external">
          "Society guideline links: Sepsis in neonates"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/110423.html" rel="external">
          "Society guideline links: Bacterial meningitis in infants and children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive care
         </strong>
         – Neonates with bacterial meningitis should receive initial care in an intensive care unit. Supportive care may include (see
         <a class="local">
          'Supportive care'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Management of cardiovascular instability or shock (see
         <a class="medical medical_review" href="/z/d/html/5039.html" rel="external">
          "Neonatal shock: Etiology, clinical manifestations, and evaluation"
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Appropriate respiratory support as needed (see
         <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">
          "Respiratory support, oxygen delivery, and oxygen monitoring in the newborn"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5032.html" rel="external">
          "Overview of mechanical ventilation in neonates"
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Careful fluid therapy, avoiding both hypo- and hypervolemia (see
         <a class="medical medical_review" href="/z/d/html/5065.html" rel="external">
          "Fluid and electrolyte therapy in newborns"
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prevention and management of hypoglycemia (see
         <a class="medical medical_review" href="/z/d/html/101425.html" rel="external">
          "Management and outcome of neonatal hypoglycemia"
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Control of seizures (see
         <a class="medical medical_review" href="/z/d/html/6201.html" rel="external">
          "Treatment of neonatal seizures"
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nutritional support (see
         <a class="medical medical_review" href="/z/d/html/5014.html" rel="external">
          "Approach to enteral nutrition in the premature infant"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15634.html" rel="external">
          "Parenteral nutrition in infants and children"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Empiric antimicrobial therapy
         </strong>
         – Broad-spectrum antimicrobial therapy should be initiated as soon as possible in neonates with suspected meningitis. The choice of the initial empiric regimen is based on the likely pathogens  (
         <a class="graphic graphic_table graphicRef61061" href="/z/d/graphic/61061.html" rel="external">
          table 1
         </a>
         ) and local susceptibility patterns. (see
         <a class="local">
          'Empiric therapy'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial empiric coverage for neonatal sepsis
         </strong>
         – Often, at the first sign of illness, empiric therapy for neonatal sepsis is initiated as summarized in the table  (
         <a class="graphic graphic_table graphicRef102574" href="/z/d/graphic/102574.html" rel="external">
          table 2
         </a>
         ) and discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5046.html" rel="external">
          "Management and outcome of sepsis in term and late preterm neonates", section on 'Initial empiric therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adjusting the empiric coverage once meningitis is suspected
         </strong>
         – For neonates with clinical evidence of meningitis (eg, critical illness, cerebrospinal fluid [CSF] pleocytosis, organism present on CSF Gram stain, or other suggestive CSF parameters), we suggest modifying the empiric regimen by substituting an extended-spectrum cephalosporin (eg,
         <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">
          cefotaxime
         </a>
         [where available],
         <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">
          ceftazidime
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">
          cefepime
         </a>
         ) for the aminoglycoside (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Coverage for herpes simplex virus (HSV)
         </strong>
         – For most neonates with CSF pleocytosis and negative CSF Gram stain, empiric
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         therapy for HSV is warranted (after performing appropriate testing), as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6040.html" rel="external">
          "Neonatal herpes simplex virus infection: Management and prevention", section on 'Initial antiviral therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitive antibiotic therapy
         </strong>
         – Once the causative agent and its in vitro antimicrobial susceptibility pattern are known, empiric antimicrobial therapy should be altered accordingly (see
         <a class="local">
          'Definitive therapy'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Group B streptococcus (GBS)
         </strong>
         – Treatment of neonatal GBS infections, including GBS meningitis, is summarized in the table and discussed in detail separately  (
         <a class="graphic graphic_table graphicRef66906" href="/z/d/graphic/66906.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5961.html" rel="external">
          "Group B streptococcal infection in neonates and young infants", section on 'Definitive therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           Escherichia coli
          </em>
         </strong>
         <strong>
          and other gram-negatives
         </strong>
         – Treatment depends on the susceptibility pattern.
         <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">
          Ampicillin
         </a>
         is used for ampicillin-susceptible strains of
         <em>
          E. coli
         </em>
         . Ampicillin-resistant organisms usually are initially treated with a combination of an extended-spectrum cephalosporin plus an aminoglycoside (eg,
         <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">
          gentamicin
         </a>
         ); the aminoglycoside is discontinued once sterility of the CSF is documented. Infections caused by multidrug resistant pathogens (eg, AmpC beta-lactamase or extended-spectrum beta-lactamase producing organisms) are treated with
         <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">
          meropenem
         </a>
         . Treatment for carbapenemase-producing gram-negative organisms should be based upon susceptibility testing by the microbiology laboratory. Treatment duration is for a minimum of 21 days. (See
         <a class="local">
          'Escherichia coli and other gram-negative organisms'
         </a>
         above and
         <a class="local">
          'Duration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other
         </strong>
         – Antibiotic regimens for other causes of neonatal meningitis are summarized above. (See
         <a class="local">
          'Other pathogens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring
         </strong>
         – The response to therapy and the potential development of complications are monitored clinically, through serial neurologic examinations, repeat lumbar puncture (LP), and neuroimaging (see
         <a class="local">
          'Monitoring response to therapy'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Most neonates should undergo repeat LP 24 to 48 hours after initiation of antibiotic therapy to document sterilization of the CSF. (See
         <a class="local">
          'Repeat lumbar puncture'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We perform neuroimaging (typically with magnetic resonance imaging [MRI]) 48 to 72 hours before the anticipated discontinuation of antimicrobial therapy in all neonates with bacterial meningitis, even in those with an apparently uncomplicated course. Neuroimaging may be warranted earlier in the course for neonates with signs suggesting neurologic complications. (See
         <a class="local">
          'Neuroimaging'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6017.html" rel="external">
          "Bacterial meningitis in the neonate: Neurologic complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcome
         </strong>
         – In the contemporary era, the mortality of neonatal bacterial meningitis is approximately 10 percent. Approximately 15 to 20 percent of survivors have moderate to severe disability, and approximately 30 to 35 percent have mild disability. (See
         <a class="local">
          'Outcome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up
         </strong>
         – Long-term follow-up for survivors of neonatal meningitis includes monitoring of hearing, visual acuity, and developmental milestones. (See
         <a class="local">
          'Follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011; 364:2016.
          </a>
         </li>
         <li class="breakAll">
          Nizet V, Klein JO. Bacterial sepsis and meningitis. In: Infectious Diseases of the Fetus and Newborn Infant, 8th ed, Wilson CS, Nizet V, Maldonado YA, Remington JS, Klein JO (Eds), Elsevier Saunders, Philadelphia 2016. p.217.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donnelly PC, Sutich RM, Easton R, et al. Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the Literature. Paediatr Drugs 2017; 19:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley JS, Wassel RT, Lee L, Nambiar S. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics 2009; 123:e609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alarcon A, Peña P, Salas S, et al. Neonatal early onset Escherichia coli sepsis: trends in incidence and antimicrobial resistance in the era of intrapartum antimicrobial prophylaxis. Pediatr Infect Dis J 2004; 23:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flannery DD, Akinboyo IC, Mukhopadhyay S, et al. Antibiotic Susceptibility of Escherichia coli Among Infants Admitted to Neonatal Intensive Care Units Across the US From 2009 to 2017. JAMA Pediatr 2021; 175:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byington CL, Rittichier KK, Bassett KE, et al. Serious bacterial infections in febrile infants younger than 90 days of age: the importance of ampicillin-resistant pathogens. Pediatrics 2003; 111:964.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Serious neonatal bacterial infections caused by enterobacteriaceae (including septicemia and meningitis). In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.311.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bryan CS, John JF Jr, Pai MS, Austin TL. Gentamicin vs cefotaxime for therapy of neonatal sepsis. Relationship to drug resistance. Am J Dis Child 1985; 139:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lautenbach E, Patel JB, Bilker WB, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aguilar J, Urday-Cornejo V, Donabedian S, et al. Staphylococcus aureus meningitis: case series and literature review. Medicine (Baltimore) 2010; 89:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Group B streptococcal infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.707.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daoud AS, Batieha A, Al-Sheyyab M, et al. Lack of effectiveness of dexamethasone in neonatal bacterial meningitis. Eur J Pediatr 1999; 158:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okike IO, Ladhani SN, Johnson AP, et al. Clinical Characteristics and Risk Factors for Poor Outcome in Infants Less Than 90 Days of Age With Bacterial Meningitis in the United Kingdom and Ireland. Pediatr Infect Dis J 2018; 37:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heath PT, Nik Yusoff NK, Baker CJ. Neonatal meningitis. Arch Dis Child Fetal Neonatal Ed 2003; 88:F173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pong A, Bradley JS. Bacterial meningitis and the newborn infant. Infect Dis Clin North Am 1999; 13:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah DK, Daley AJ, Hunt RW, et al. Cerebral white matter injury in the newborn following Escherichia coli meningitis. Eur J Paediatr Neurol 2005; 9:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raju VS, Rao MN, Rao VS. Cranial sonography in pyogenic meningitis in neonates and infants. J Trop Pediatr 1995; 41:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yikilmaz A, Taylor GA. Sonographic findings in bacterial meningitis in neonates and young infants. Pediatr Radiol 2008; 38:129.
          </a>
         </li>
         <li class="breakAll">
          Volpe JJ. Bacterial and fungal intracranial infections. In: Neurology of the Newborn, 6th ed, Elsevier, 2018. p.1050.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell JR, Diacovo T, Baker CJ. Serratia marcescens meningitis in neonates. Pediatr Infect Dis J 1992; 11:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renier D, Flandin C, Hirsch E, Hirsch JF. Brain abscesses in neonates. A study of 30 cases. J Neurosurg 1988; 69:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iversen C, Lehner A, Mullane N, et al. Identification of "Cronobacter" spp. (Enterobacter sakazakii). J Clin Microbiol 2007; 45:3814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phan H, Lehman D. Cerebral abscess complicating Proteus mirabilis meningitis in a newborn infant. J Child Neurol 2012; 27:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuadros EN, Castilla CY, Algarra CM, et al. Medical and neurosurgical management of Citrobacter koseri, a rare cause of neonatal meningitis. J Med Microbiol 2014; 63:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaves CEV, Brandão MLL, Lacerda MLGG, et al. Fatal Cronobacter sakazakii Sequence Type 494 Meningitis in a Newborn, Brazil. Emerg Infect Dis 2018; 24:1948.
          </a>
         </li>
         <li class="breakAll">
          Harrison GJ. Approach to infections in the fetus and newborn. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 7th, Cherry JD, Harrison GJ, Kaplan SL, et al (Eds), Elsevier Saunders, Philadelphia 2014. p.877.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harvey D, Holt DE, Bedford H. Bacterial meningitis in the newborn: a prospective study of mortality and morbidity. Semin Perinatol 1999; 23:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Louvois J, Halket S, Harvey D. Neonatal meningitis in England and Wales: sequelae at 5 years of age. Eur J Pediatr 2005; 164:730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basmaci R, Bonacorsi S, Bidet P, et al. Escherichia Coli Meningitis Features in 325 Children From 2001 to 2013 in France. Clin Infect Dis 2015; 61:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ouchenir L, Renaud C, Khan S, et al. The Epidemiology, Management, and Outcomes of Bacterial Meningitis in Infants. Pediatrics 2017; 140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holt DE, Halket S, de Louvois J, Harvey D. Neonatal meningitis in England and Wales: 10 years on. Arch Dis Child Fetal Neonatal Ed 2001; 84:F85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brumbaugh JE, Bell EF, Do BT, et al. Incidence of and Neurodevelopmental Outcomes After Late-Onset Meningitis Among Children Born Extremely Preterm. JAMA Netw Open 2022; 5:e2245826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klinger G, Chin CN, Beyene J, Perlman M. Predicting the outcome of neonatal bacterial meningitis. Pediatrics 2000; 106:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unhanand M, Mustafa MM, McCracken GH Jr, Nelson JD. Gram-negative enteric bacillary meningitis: a twenty-one-year experience. J Pediatr 1993; 122:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson SG, Gilbert GL. Neonatal gram negative meningitis: a 10-year review, with reference to outcome and relapse of infection. J Paediatr Child Health 1990; 26:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levent F, Baker CJ, Rench MA, Edwards MS. Early outcomes of group B streptococcal meningitis in the 21st century. Pediatr Infect Dis J 2010; 29:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards MS, Rench MA, Haffar AA, et al. Long-term sequelae of group B streptococcal meningitis in infants. J Pediatr 1985; 106:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           May M, Daley AJ, Donath S, et al. Early onset neonatal meningitis in Australia and New Zealand, 1992-2002. Arch Dis Child Fetal Neonatal Ed 2005; 90:F324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franco SM, Cornelius VE, Andrews BF. Long-term outcome of neonatal meningitis. Am J Dis Child 1992; 146:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg RG, Benjamin DK Jr, Cohen-Wolkowiez M, et al. Repeat lumbar punctures in infants with meningitis in the neonatal intensive care unit. J Perinatol 2011; 31:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ter Horst HJ, van Olffen M, Remmelts HJ, et al. The prognostic value of amplitude integrated EEG in neonatal sepsis and/or meningitis. Acta Paediatr 2010; 99:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doctor BA, Newman N, Minich NM, et al. Clinical outcomes of neonatal meningitis in very-low birth-weight infants. Clin Pediatr (Phila) 2001; 40:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoll BJ, Hansen NI, Adams-Chapman I, et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 2004; 292:2357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008; 299:2056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Libster R, Edwards KM, Levent F, et al. Long-term outcomes of group B streptococcal meningitis. Pediatrics 2012; 130:e8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lohrmann F, Hufnagel M, Kunze M, et al. Neonatal invasive disease caused by Streptococcus agalactiae in Europe: the DEVANI multi-center study. Infection 2023; 51:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puopolo KM, Mukhopadhyay S, Hansen NI, et al. Group B Streptococcus Infection in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years. Clin Infect Dis 2022; 75:1405.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6016 Version 44.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21612470" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Bacterial meningitis in the United States, 1998-2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21612470" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Bacterial meningitis in the United States, 1998-2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27718120" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19289450" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15071281" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Neonatal early onset Escherichia coli sepsis: trends in incidence and antimicrobial resistance in the era of intrapartum antimicrobial prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33165599" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Antibiotic Susceptibility of Escherichia coli Among Infants Admitted to Neonatal Intensive Care Units Across the US From 2009 to 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12728072" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Serious bacterial infections in febrile infants younger than 90 days of age: the importance of ampicillin-resistant pathogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12728072" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Serious bacterial infections in febrile infants younger than 90 days of age: the importance of ampicillin-resistant pathogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3904403" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Gentamicin vs cefotaxime for therapy of neonatal sepsis. Relationship to drug resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11283805" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15494903" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Practice guidelines for the management of bacterial meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20517182" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Staphylococcus aureus meningitis: case series and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10094445" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Lack of effectiveness of dexamethasone in neonatal bacterial meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29384979" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical Characteristics and Risk Factors for Poor Outcome in Infants Less Than 90 Days of Age With Bacterial Meningitis in the United Kingdom and Ireland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12719388" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Neonatal meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10470563" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Bacterial meningitis and the newborn infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15701561" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Cerebral white matter injury in the newborn following Escherichia coli meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7776399" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Cranial sonography in pyogenic meningitis in neonates and infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17611750" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Sonographic findings in bacterial meningitis in neonates and young infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17611750" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Sonographic findings in bacterial meningitis in neonates and young infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1408491" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Serratia marcescens meningitis in neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3057126" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Brain abscesses in neonates. A study of 30 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17881547" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Identification of "Cronobacter" spp. (Enterobacter sakazakii).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22114212" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Cerebral abscess complicating Proteus mirabilis meningitis in a newborn infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24243285" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Medical and neurosurgical management of Citrobacter koseri, a rare cause of neonatal meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30226186" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Fatal Cronobacter sakazakii Sequence Type 494 Meningitis in a Newborn, Brazil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30226186" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Fatal Cronobacter sakazakii Sequence Type 494 Meningitis in a Newborn, Brazil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10405191" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Bacterial meningitis in the newborn: a prospective study of mortality and morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16136294" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Neonatal meningitis in England and Wales: sequelae at 5 years of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25944342" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Escherichia Coli Meningitis Features in 325 Children From 2001 to 2013 in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28600447" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The Epidemiology, Management, and Outcomes of Bacterial Meningitis in Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11207221" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Neonatal meningitis in England and Wales: 10 years on.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36480199" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Incidence of and Neurodevelopmental Outcomes After Late-Onset Meningitis Among Children Born Extremely Preterm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10969090" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Predicting the outcome of neonatal bacterial meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8419603" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Gram-negative enteric bacillary meningitis: a twenty-one-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2257183" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Neonatal gram negative meningitis: a 10-year review, with reference to outcome and relapse of infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20555292" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Early outcomes of group B streptococcal meningitis in the 21st century.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3889248" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Long-term sequelae of group B streptococcal meningitis in infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15878934" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Early onset neonatal meningitis in Australia and New Zealand, 1992-2002.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1621658" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Long-term outcome of neonatal meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21164430" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Repeat lumbar punctures in infants with meningitis in the neonatal intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19889102" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The prognostic value of amplitude integrated EEG in neonatal sepsis and/or meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11583045" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Clinical outcomes of neonatal meningitis in very-low birth-weight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15547163" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18460666" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22689869" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Long-term outcomes of group B streptococcal meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36547864" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Neonatal invasive disease caused by Streptococcus agalactiae in Europe: the DEVANI multi-center study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35323895" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Group B Streptococcus Infection in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
